192 related articles for article (PubMed ID: 37837660)
1. Vedolizumab Efficacy Is Associated With Decreased Intracolonic Dendritic Cells, Not Memory T Cells.
Boden EK; Kongala R; Hindmarch DC; Shows DM; Juarez JG; Lord JD
Inflamm Bowel Dis; 2024 May; 30(5):704-717. PubMed ID: 37837660
[TBL] [Abstract][Full Text] [Related]
2. Mucosal α4β7+ Lymphocytes and MAdCAM+ Venules Predict Response to Vedolizumab in Ulcerative Colitis.
Roosenboom B; Wahab PJ; Smids C; Meijer J; Kemperman LGJM; Groenen MJM; van Lochem EG; Horjus Talabur Horje CS
Inflamm Bowel Dis; 2024 Jun; 30(6):930-938. PubMed ID: 37436917
[TBL] [Abstract][Full Text] [Related]
3. Dissecting Common and Unique Effects of Anti-α4β7 and Anti-Tumor Necrosis Factor Treatment in Ulcerative Colitis.
Veny M; Garrido-Trigo A; Corraliza AM; Masamunt MC; Bassolas-Molina H; Esteller M; Arroyes M; Tristán E; Fernández-Clotet A; Ordás I; Ricart E; Esteve M; Panés J; Salas A
J Crohns Colitis; 2021 Mar; 15(3):441-452. PubMed ID: 32926095
[TBL] [Abstract][Full Text] [Related]
4. Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease.
Boden EK; Shows DM; Chiorean MV; Lord JD
Dig Dis Sci; 2018 Sep; 63(9):2419-2429. PubMed ID: 29372476
[TBL] [Abstract][Full Text] [Related]
5. Immunological Variables Associated With Clinical and Endoscopic Response to Vedolizumab in Patients With Inflammatory Bowel Diseases.
Coletta M; Paroni M; Alvisi MF; De Luca M; Rulli E; Mazza S; Facciotti F; Lattanzi G; Strati F; Abrignani S; Fantini MC; Vecchi M; Geginat J; Caprioli F
J Crohns Colitis; 2020 Sep; 14(9):1190-1201. PubMed ID: 32100016
[TBL] [Abstract][Full Text] [Related]
6. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
Ungar B; Kopylov U; Yavzori M; Fudim E; Picard O; Lahat A; Coscas D; Waterman M; Haj-Natour O; Orbach-Zingboim N; Mao R; Chen M; Chowers Y; Eliakim R; Ben-Horin S
Clin Gastroenterol Hepatol; 2018 May; 16(5):697-705.e7. PubMed ID: 29223444
[TBL] [Abstract][Full Text] [Related]
7. An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab.
Wyant T; Fedyk E; Abhyankar B
J Crohns Colitis; 2016 Dec; 10(12):1437-1444. PubMed ID: 27252400
[TBL] [Abstract][Full Text] [Related]
8. Baseline levels of dynamic CD4
Allner C; Melde M; Becker E; Fuchs F; Mühl L; Klenske E; Müller L; Morgenstern N; Fietkau K; Hirschmann S; Atreya R; Atreya I; Neurath MF; Zundler S
BMC Gastroenterol; 2020 Apr; 20(1):103. PubMed ID: 32293299
[TBL] [Abstract][Full Text] [Related]
9. The α4β1 Homing Pathway Is Essential for Ileal Homing of Crohn's Disease Effector T Cells In Vivo.
Zundler S; Fischer A; Schillinger D; Binder MT; Atreya R; Rath T; Lopez-Pósadas R; Voskens CJ; Watson A; Atreya I; Neufert C; Neurath MF
Inflamm Bowel Dis; 2017 Mar; 23(3):379-391. PubMed ID: 28221249
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of vedolizumab in the treatment of ulcerative colitis.
Domènech E; Gisbert JP
Gastroenterol Hepatol; 2016 Dec; 39(10):677-686. PubMed ID: 26948838
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.
McLean LP; Cross RK
Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):833-42. PubMed ID: 27096357
[TBL] [Abstract][Full Text] [Related]
12. Enterocyte dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin expression in inflammatory bowel disease.
Zeng JQ; Xu CD; Zhou T; Wu J; Lin K; Liu W; Wang XQ
World J Gastroenterol; 2015 Jan; 21(1):187-95. PubMed ID: 25574091
[TBL] [Abstract][Full Text] [Related]
13. Mucosal Eosinophilia Is an Independent Predictor of Vedolizumab Efficacy in Inflammatory Bowel Diseases.
Kim EM; Randall C; Betancourt R; Keene S; Lilly A; Fowler M; Dellon ES; Herfarth HH
Inflamm Bowel Dis; 2020 Jul; 26(8):1232-1238. PubMed ID: 31633167
[TBL] [Abstract][Full Text] [Related]
14. Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.
Zeissig S; Rosati E; Dowds CM; Aden K; Bethge J; Schulte B; Pan WH; Mishra N; Zuhayra M; Marx M; Paulsen M; Strigli A; Conrad C; Schuldt D; Sinha A; Ebsen H; Kornell SC; Nikolaus S; Arlt A; Kabelitz D; Ellrichmann M; Lützen U; Rosenstiel PC; Franke A; Schreiber S
Gut; 2019 Jan; 68(1):25-39. PubMed ID: 29730603
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo.
Fischer A; Zundler S; Atreya R; Rath T; Voskens C; Hirschmann S; López-Posadas R; Watson A; Becker C; Schuler G; Neufert C; Atreya I; Neurath MF
Gut; 2016 Oct; 65(10):1642-64. PubMed ID: 26209553
[TBL] [Abstract][Full Text] [Related]
16. Vedolizumab Induces Long-term Mucosal Healing in Patients With Crohn's Disease and Ulcerative Colitis.
Noman M; Ferrante M; Bisschops R; De Hertogh G; Van den Broeck K; Rans K; Rutgeerts P; Vermeire S; Van Assche G
J Crohns Colitis; 2017 Sep; 11(9):1085-1089. PubMed ID: 28369329
[TBL] [Abstract][Full Text] [Related]
17. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.
Stallmach A; Langbein C; Atreya R; Bruns T; Dignass A; Ende K; Hampe J; Hartmann F; Neurath MF; Maul J; Preiss JC; Schmelz R; Siegmund B; Schulze H; Teich N; von Arnim U; Baumgart DC; Schmidt C
Aliment Pharmacol Ther; 2016 Dec; 44(11-12):1199-1212. PubMed ID: 27714831
[TBL] [Abstract][Full Text] [Related]
18. Responsiveness to Vedolizumab Therapy in Ulcerative Colitis is Associated With Alterations in Immune Cell-Cell Communications.
Hsu P; Choi EJ; Patel SA; Wong WH; Olvera JG; Yao P; Liu YC; Tsai MS; Wang W; Boland BS; Chang JT
Inflamm Bowel Dis; 2023 Oct; 29(10):1602-1612. PubMed ID: 37235748
[TBL] [Abstract][Full Text] [Related]
19. Use of Vedolizumab in Inflammatory Bowel Disease: A Single-Center Experience.
Erdoğan Ç; Yeşil B; Bacaksız F; Arı D; Gökbulut V; Yüksel M; Özderin Özin Y; Kayaçetin E
Turk J Gastroenterol; 2022 Oct; 33(10):831-837. PubMed ID: 35946879
[TBL] [Abstract][Full Text] [Related]
20. Vedolizumab and etrolizumab for ulcerative colitis: twins or simple cousins?
D'Amico F; Danese S; Peyrin-Biroulet L
Expert Opin Biol Ther; 2020 Apr; 20(4):353-361. PubMed ID: 31951748
[No Abstract] [Full Text] [Related]
[Next] [New Search]
